Pharma Pioneer

Eilean Therapeutics Launches First Patient Trial for Menin Inhibitor Balamenib

19 May 2024
2 min read

Eilean Therapeutics LLC, a company specializing in biopharmaceutical innovations, announced that its Australian subsidiary has received approval from the Human Research Ethics Committee to begin a Phase 1 clinical trial of balamenib (ZE63-0302). This trial, conducted under the Clinical Trial Notification scheme of the Australian Therapeutics Goods Administration, aims to assess the safety, pharmacokinetics, and target engagement of this highly selective menin–KMT2A binding interaction inhibitor in healthy volunteers through a single ascending dose study.

CEO Iain Dukes emphasized that this first human study of balamenib in Australia signifies a significant milestone for the company, as it advances its portfolio of treatments targeting blood cancers. Balamenib boasts a unique pre-clinical profile that offers superior safety, tolerability, and outpatient treatment feasibility compared to similar drugs, enabling effective treatment of AML both independently and in combination with other therapies.

Balamenib (ZE63-0302) is an oral inhibitor focusing on the menin-KMT2A interaction. Pre-clinical studies have shown its potency against KMT2Ar specific cell lines and in xenograft models, either alone or when combined with Eilean Therapeutics' other treatments like eiletoclax and lomonitinib. It shows an improved safety profile, lacking QTc prolongation and avoiding interaction with cytochrome P450 3A4 metabolism, alongside significantly lower susceptibility to common menin mutations seen in clinical settings.

Eilean Therapeutics LLC, co-founded by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, is committed to discovering advanced small molecule inhibitors to target escape mutations in both blood and solid cancers. Utilizing a proprietary hybrid AI/ML platform from Expert Systems Inc., the company accelerates the development of groundbreaking therapies, aiming to become a leader in treating various malignancies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Regulus Therapeutics Reports Favorable Phase 1b MAD Trial Results for ADPKD Drug RGLS8429
Pharma Pioneer
3 min read
Regulus Therapeutics Reports Favorable Phase 1b MAD Trial Results for ADPKD Drug RGLS8429
19 May 2024
Regulus Therapeutics has reported promising outcomes from the second group of participants in a Phase 1b clinical trial for a new drug, RGLS8429.
Read →
KVA12123 Advances in VISTA-101 Trial with Promising Early Clinical Results
Pharma Pioneer
3 min read
KVA12123 Advances in VISTA-101 Trial with Promising Early Clinical Results
19 May 2024
The trial is assessing the efficacy of KVA12123, a VISTA-blocking immunotherapy, both as a standalone treatment and in conjunction with Merck’s KEYTRUDA® (pembrolizumab).
Read →
Roche's Alzheimer's Drug Shows Promise in Mid-Stage Trials
Pharma Pioneer
2 min read
Roche's Alzheimer's Drug Shows Promise in Mid-Stage Trials
19 May 2024
Roche has recently announced at an online investor event that their experimental drug for Alzheimer's disease, trontinemab.
Read →
Clearmind Secures Approval for Psychedelic AUD Clinical Trial
Pharma Pioneer
2 min read
Clearmind Secures Approval for Psychedelic AUD Clinical Trial
19 May 2024
The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.